UniProt Q8NEV4 · PDB · AlphaFold · Substrate: MBP · Clone: aa 1-434
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 93.4% | 6.6% | 78.23 | 0.534 |
| 2 | Brigatinib | 84.9% | 15.1% | 82.96 | 0.513 |
| 3 | Gilteritinib | 81.3% | 18.7% | 88.97 | 0.506 |
| 4 | Ceritinib | 79.4% | 20.6% | 95.44 | 0.618 |
| 5 | Midostaurin | 58.0% | 42.0% | 78.64 | 0.500 |
| 6 | Alectinib | 52.1% | 47.9% | 95.49 | 0.651 |
| 7 | Vemurafenib | 50.4% | 49.6% | 96.49 | 0.598 |
| 8 | Netarsudil | 41.6% | 58.4% | 93.22 | 0.676 |
| 9 | Abemaciclib | 32.9% | 67.1% | 91.48 | 0.563 |
| 10 | Sunitinib | 27.5% | 72.5% | 91.73 | 0.524 |
| 11 | Osimertinib | 27.2% | 72.8% | 97.24 | 0.733 |
| 12 | Defactinib | 24.7% | 75.3% | 92.68 | 0.450 |
| 13 | Abrocitinib | 21.5% | 78.5% | 99.50 | 0.581 |
| 14 | Ripretinib | 20.9% | 79.1% | 92.95 | 0.674 |
| 15 | Tivozanib | 20.0% | 80.0% | 92.42 | 0.673 |
| 16 | Lazertinib | 20.0% | 80.0% | 97.47 | 0.674 |
| 17 | Lorlatinib | 19.9% | 80.1% | 97.24 | 0.694 |
| 18 | Bosutinib | 19.4% | 80.6% | 87.22 | 0.555 |
| 19 | Pacritinib | 17.3% | 82.7% | 88.64 | 0.452 |
| 20 | Erlotinib | 16.3% | 83.7% | 99.75 | 0.695 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.16
- Epithelial log2(TPM+1): 0.26
- Fold change: -0.10
- Status: No significant change
Selectivity landscape vs inhibition on MYO3A
Each point is one of the 92 approved drugs; color = inhibition % on MYO3A.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…